Haemolytic uraemic syndrome

Abstract : Haemolytic uraemic syndrome is a form of thrombotic microangiopathy affecting predominantly the kidney and characterised by a triad of thrombocytopenia, mechanical haemolytic anaemia, and acute kidney injury. The term encompasses several disorders: shiga toxin-induced and pneumococcus-induced haemolytic uraemic syndrome, haemolytic uraemic syndrome associated with complement dysregulation or mutation of diacylglycerol kinase ε, haemolytic uraemic syndrome related to cobalamin C defect, and haemolytic uraemic syndrome secondary to a heterogeneous group of causes (infections, drugs, cancer, and systemic diseases). In the past two decades, experimental, genetic, and clinical studies have helped to decipher the pathophysiology of these various forms of haemolytic uraemic syndrome and undoubtedly improved diagnostic approaches. Moreover, a specific mechanism-based treatment has been made available for patients affected by atypical haemolytic uraemic syndrome due to complement dysregulation. Such treatment is, however, still absent for several other disease types, including shiga toxin-induced haemolytic uraemic syndrome.
Document type :
Journal articles
Complete list of metadatas

Cited literature [162 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02155934
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Friday, June 14, 2019 - 9:04:33 AM
Last modification on : Sunday, June 16, 2019 - 1:46:50 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-02155934, version 1

Citation

Fadi Fakhouri, Julien Zuber, Véronique Frémeaux-Bacchi, Chantal Loirat. Haemolytic uraemic syndrome. The Lancet, Elsevier, 2017. ⟨inserm-02155934⟩

Share

Metrics

Record views

99